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Hepcidin, produced by the liver, is the master regulator of iron balance. Serum
hepcidin is increased by high iron stores, blocks intestinal iron absorption, and
impairs storage iron release. Conversely, iron deﬁciency lowers hepcidin levels and
enhances intestinal iron absorption and the release of storage iron. As with ferritin,
hepcidin is an acute phase reactant. Consequently, inﬂammation increases hepci-
din and leads to impaired iron absorption, lowers serum iron and transferrin
saturation, and contributes to the anemia of chronic kidney disease (CKD). We
review the physiology of iron absorption, its relationship to hepcidin and the
transmembrane iron transporter ferroportin, the role of hepcidin in CKD related
anemia, and the possible diagnostic implications and limitations of using hepcidin
as a marker of iron status.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepcidin was ﬁrst isolated from human urine in the year
2000 and initially deﬁned as solely an antimicrobial peptide
[1,2]. Although now accepted as the key regulator of iron
balance, a role for hepcidin in iron metabolism was not
recognized until 2001 when animal studies demonstrated
that hepatic mRNA synthesis was induced by iron loading [3].
Since then, the structure, function, and regulation of hepcidin
in normal iron balance, hereditary hemochromatosis, and in
the anemias of chronic disease and chronic kidney disease
(CKD) have been studied extensively. This review will discuss
the physiology of iron absorption, the role of hepcidin in CKD-
related anemia, and the possible diagnostic implications and
limitations of using hepcidin as a marker.rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
ashington University,
Coyne).The importance of iron and iron balance
Iron is the fourth most abundant element in the earth’s
crust, yet the average adult human body contains only 3–4 g,
and iron deﬁciency is the most common cause of anemia
worldwide. Since there are no signiﬁcant physiologic mechan-
isms to regulate iron loss, iron homeostasis is dependent
upon the tight link between intestinal iron absorption and
total body iron requirements [4]. Intestinal iron absorption
amounts to 1–2 mg of iron per day calculated from a dietary
iron intake of 12–18 mg/day [5], and 1–2 mg of iron is lost on
a daily basis through shedding of intestinal enterocytes,
sweat, blood loss, and skin sloughing [6].
This intestinal iron absorption is essential as iron is a major
component of heme in hemoglobin and myoglobin as well as
an important cofactor in many redox enzymes [7]. Although
crucial for life, free iron is toxic to cells [8], thus iron is
maintained overwhelmingly in a bound or chelated state.
Dietary iron absorption occurs almost exclusively in the
duodenum, where it can be absorbed as heme (which is the
most common dietary iron in Western cultures) or iron salts
or nonheme (inorganic) irons such as ferrous sulfate [9].ublished by Elsevier. This is an open access article under the CC BY-NC-
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intestinal lumen and transported as intact iron porphyrin across
the brush border [10]. Nonheme ferric iron (Fe3þ) is reduced to
ferrous iron (Fe2þ) by a ferric reductase enzyme (also called
duodenal cytochrome b) on the enterocytes’ brush border [11],
which then is transported across the apical enterocyte mem-
brane by divalent metal transporter 1 (DMT1), a proton-coupled
ion transporter, into the cell [5]. The possible fate of Fe2þ is to
either be stored within intracellular ferritin or transported to the
basolateral membrane, where it is exported by ferroportin1 into
the plasma. Ferroportin is a transmembrane transporter for iron.
Located in the basolateral membrane of duodenal cells and in
the membrane of all iron exporting cells in the body, ferroportin
exports Fe2þ from the cell.
Transport of iron from the cell to the plasma is facilitated by
the oxidation of Fe2þ to Fe3þ , which is catalyzed by the
ceruloplasmin homolog hephestin [12]. Ferric iron is then rapidly
bound to transferrin. This exquisite intestinal system provides
iron to the body while protecting tissues against the oxidative
effects of free iron. Co-ingested minerals may also alter intestinal
iron absorption. Ascorbic acid can enhance nonheme absorption
by reducing Fe3þ to the Fe2þ form, while calcium, zinc, and
magnesium impair absorption. Iron deﬁciency anemia plays a
large role in upregulation of duodenal DMT1, DcytB, and ferro-
portin1 mRNA levels along with protein expression [13].The role of hepcidin and ferroportin in iron regulation
Hepcidin is a 25 amino acid peptide that was ﬁrst identiﬁed
in urine and plasma as an antimicrobial peptide [14]. It is
synthesized in hepatocytes as a larger, inactive pre-prohepcidin,
which is then cleaved by the prohormone convertase furin to
generate mature hepcidin [15]. Hepcidin is encoded by theIntestinalFe3+ Fe2+
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Figure 1. Impact of iron stores and hepcidin levels on duodenal iron
deﬁciency and low hepcidin blood levels. (B) Duodenal iron absorption un
replete or there is signiﬁcant inﬂammation. Refer to the text for further deHamp gene and its expression is promoted simultaneously
by several factors, including transferrin-bound iron [16], pro-
inﬂammatory cytokines [17], transferrin receptor 2 [18], hemo-
juvelin [19], the transcription factor Smad4 [20], HFE protein
[21], and several bone morphogenic proteins [22].
The main role of hepcidin is to control the ﬂux of iron into
plasma by regulating ferroportin expression on the surface of
cells. Under normal physiologic conditions, ferroportin is pre-
sent on the basolateral membrane of duodenal enterocytes, and
the surface of hepatocytes and macrophages. Surface expres-
sion of ferroportin is essential for iron to enter the systemic
circulation (Fig. 1A). Hepcidin’s main action is to bind to
ferroportin, which results in internalization and degradation
of the complex, effectively preventing duodenal iron absorption
and reducing iron release from macrophages (Fig. 1B) [23].
Because duodenal cells are eventually sloughed, intestinal iron
absorption is prevented, while decreased release of iron from
storage results in reduced circulating plasma iron.
Hepcidin levels decline when iron stores are low, permitting
enhanced iron absorption. Hepcidin levels increase in response
to high iron stores and high serum iron, and thus protects
against iron overload [24,25]. This was demonstrated in a
mouse model in which constitutive overexpression of hepcidin
resulted in death from iron deﬁciency anemia [26]. A serine
protease also expressed in the liver, TMPRSS6, is thought to
participate in a transmembrane signaling pathway that is
triggered by iron deﬁciency anemia to block transcription of
the gene for hepcidin, Hamp, resulting in lower hepcidin
production in order to permit dietary iron absorption [27].
Aside from iron, hepcidin is also clinically regulated by
anemia, hypoxia, and inﬂammation [14]. Human hepatocytes
increase hepcidin mRNA in the presence of IL-6 or lipopolysac-
charide and in the presence of IL-6 produced by monocytes
exposed to lipopolysaccharide [17]. In one human case study,Apical side
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complex
Hepcidin
= DMT1, divalent metal transporter 1
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absorption. (A) Duodenal iron absorption under conditions of iron
der conditions of high hepcidin levels that occur when iron stores are
tails.
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As an acute phase reactant, hepcidin activity therefore mirrors
ferritin, which makes the interpretation of iron studies in the
presence of inﬂammation very difﬁcult [7,28]. Lastly, hypoxemia
and anemia appear to suppress hepcidin via the stimulation of
epoetin, which improves iron mobilization as compensation [29].Hepcidin in the CKD and dialysis populations
Given the confounding variables in managing and evaluat-
ing anemia of CKD [28], the nephrology community has long
been searching for a novel marker and predictor for iron
responsiveness. Our current biomarkers of ferritin and trans-
ferrin saturation (TSAT) are often subpar, and hepcidin has
thus been postulated to offer more deﬁnitive diagnostic
promise as it is the master regulator for iron absorption and
release of iron from reticuloendothelial stores (RES).
Many studies have demonstrated that hepcidin levels
increase progressively with severity of CKD, with predialysis
CKD patients having a two- to four-fold elevation of hepcidin,
and dialysis patients with a six- to nine-fold increase of
hepcidin [30]. Some studies have failed to demonstrate
elevated hepcidin in early CKD, and this could reﬂect differing
populations, the hepcidin assays employed, and the power of
the study to detect differences given the wide intrapatient
short-term variability in hepcidin levels [31].
Several investigators have found that hepcidin and ferritin
correlate strongly in dialysis patients [32], and it has pre-
viously been hypothesized that the inverse relationship of
glomerular ﬁltration rate (GFR) and hepcidin is due to the
known association of CKD and inﬂammation. Although ferri-
tin, an acute phase reactant, is a marker of iron stores and
inﬂammation, it has continually lacked a strong predictive
value for identifying iron responsiveness [33].
The correlation between markers of inﬂammation and
hepcidin levels has been demonstrated in several studies that
may actually preclude its clinical utility for iron status evalua-
tion in patients with inﬂammation [31,34]. This was also
supported by a study by Zaritsky and colleagues in 2009, when
the authors included erythrocyte sedimentation rate and high
sensitivity-C reactive protein (CRP) covariates in their multi-
variate analysis and concluded that the relationship between
inﬂammation and hepcidin levels persisted [35]. Not all stu-
dies, however, support this correlation between hepcidin and
inﬂammatory markers [36,37].
Furthermore, some studies have suggested no difference in
hepcidin levels between epoetin-responsive and nonresponsive
dialysis patients and no correlation between hepcidin and epoetin
dose [31,36]. While some have reported an inverse relationship
between hepcidin and epoetin with a corresponding decline in
hepcidin levels when epoetin is initiated, the variability in
hepcidin levels suggests the relationship is insufﬁcient to guide
clinical decisions regarding iron and erythropoiesis-stimulating
agent (ESA) dosing [37,38].
Animal models have suggested that elevated hepcidin
levels impair response to even large ESA doses [39], raising
suspicion that high hepcidin levels contribute to the ESA
resistance observed in some chronic hemodialysis patients.
This raises the possibility that lowering hepcidin levels or
impairing hepcidin interaction with ferroportin could be an
effective anemia treatment in CKD and dialysis patients.IV and oral iron: overcoming hepcidin-mediated
blockade
Elevated hepcidin contributes to the anemia of CKD and
the anemia of chronic inﬂammation by binding to the ferro-
portin channel and inhibiting the release of iron from macro-
phages, hepatocytes, and enterocytes. In time, this chronic
elevation of hepcidin may result in iron deﬁciency, but even
in the short term, hepcidin blockade results in ‘‘functional’’
iron deﬁciency due to impaired release of iron from the RES.
Due to this, even patients with adequate iron stores can
experience iron-restricted erythropoiesis, especially when
red blood cell production is increased by ESAs [40].
Intravenous (IV) iron supplementation has been found to
overcome hepcidin-mediated blockade and iron-restricted
erythropoiesis by improving anemia, including patients with
elevated levels of hepcidin as well as elevated CRP levels
[41,42]. IV iron can be released immediately by the macro-
phages and saturate plasma transferrin or become stored in
ferritin [43]. This effect, however, was not seen with oral iron
supplementation, presumably because hepcidin has interna-
lized the basolateral ferroportin on duodenal cells, thereby
preventing absorption.
Suppressing hepcidin’s actions could reestablish the efﬁ-
cacy of oral iron therapy for treatment of iron-restricted
erythropoiesis, and enhance release of any iron present in
the RES. Administration of an antihepcidin antibody has been
found in an animal model expressing human hepcidin to treat
inﬂammation-induced anemia [39]. Also, using a small-
interfering RNA has been shown to directly suppress hepcidin
transcription and increase serum iron levels [39]. Several
potential targets involved in hepcidin signaling and transcrip-
tion, such as anti-bone morphogenic protein (anti-BMP)
molecules, STAT3 inhibition, and HIF promoters, also can
reduce hepcidin expression [44–46].
The average hemodialysis patient loses 1.5–3.0 g of iron
per year, or 30–60 mg of iron per week. Clinical trials to date
have not demonstrated long-term harm from IV iron therapy
in dialysis patients, but trials have not been ideally designed
to fully assess safety. An IV iron supplementation strategy will
increase hepcidin levels further, and could adversely affect
long-term iron mobilization. As hemodialysis patients have
continual blood (and therefore iron) losses, the goal of IV iron
treatment should be to ﬁrst replete the iron stores, then
provide sufﬁcient IV iron to match ongoing losses.
Most dialysis patients receiving IV iron have also been
found to have hemosiderosis as determined by magnetic
resonance imaging (MRI) [47]. However, these studies are
controversial because such imaging cannot differentiate
between IV iron taken up into the RES by the liver and the
pathological deposition of iron into liver parenchymal cells.
There are several lines of evidence to suggest IV iron in
hemodialysis patients is not leading to iron overload-mediated
organ damage. There is a relatively rapid dissipation of liver iron
content as measured by MRI scanning in hemodialysis patients,
suggesting either surprisingly large ongoing blood losses, which is
highly unlikely, or the relationship of total body iron content to
MRI results is fundamentally different in hemodialysis patients
receiving IV iron products compared with patients with transfu-
sional iron overload. Patients with transfusional iron overload and
end-organ damage have 15–25 g of excess body iron, which is
more than the average hemodialysis patient receives in a lifetime,
even before accounting for the substantial iron losses due to
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and serum ferritin levels in the United States and Europe, there
have not been reports of liver or heart damage related to iron
overload. Nevertheless, all therapies have risks, and prudent
dosing of IV iron should reﬂect an assessment of estimated iron
needs and ongoing iron losses. Lastly, aggressive treatment of
anemia with ESA does not reduce cardiovascular events or lower
mortality, and therefore the urgency to treat anemia is largely
misplaced.Practical clinical implications of hepcidin testing
Several serum hepcidin assays have been developed that
correlate well to iron stores in select populations, while urinary
hepcidin and serum prohepcidin have not been clinically useful
[48,49]. Furthermore, there is a wide variability (as much as a
10-fold difference) in the level of hepcidin values reported by
various methods including surface enhanced laser desorption/
ionization time-of-ﬂight mass spectrometry (SELDI-TOF MS),
liquid chromatography mass spectrometry, competitive
enzyme-linked immunosorbent assay (ELISA), and competitive
radioimmunoassay (RIA) [50]. The reasons for these discrepan-
cies are unclear, but possible etiologies include cross-reactivity
with hepcidin metabolites, hepcidin-binding factors in the
serum, and different hepcidin standards.
In clinical practice, a low transferrin saturation (o25%)
coupled with low ferritin (o200 ng/mL in dialysis patients,
and o100 ng/mL in CKD Stage 3 and 4 patients) indicates a
high likelihood of iron deﬁciency, especially if the patient is
anemic and receiving an ESA. Such patients usually have low
hepcidin levels. Due to the direct relationship between ferritin
and hepcidin, and the broad short-term intrapatient varia-
bility in hepcidin, it is unlikely hepcidin offers any better
predictive value than ferritin. Several investigations to date
support this view [31,34,51]. Similarly, a hepcidin determina-
tion is not required in iron-replete patients exhibiting high
transferrin saturation and high ferritin.
The most difﬁcult anemic patients to manage have low
transferrin saturation coupled with high ferritin, suggesting
the anemia is due to iron deﬁciency, inﬂammation, or a
combination of those factors. Unfortunately, such patients
also have high hepcidin levels, and therefore, hepcidin does
not discriminate among these disorders and cannot guide
therapy better than our standard testing. Despite being
correlated with ferritin, hepcidin has been found to be no
better than ferritin in predicting iron stores or iron require-
ments in hemodialysis patients. Until the contribution of
inﬂammation to high hepcidin levels is eliminated or quanti-
ﬁed, hepcidin offers no superiority over ferritin and transfer-
rin saturation as markers of iron stores or iron needs.Conclusion
Hepcidin has been found to be the key regulator of iron
homeostasis and plays a key role in CKD and chronic disease
anemia as it is excreted by the kidneys and regulated by
inﬂammation. At present, the measurement of hepcidin is erratic
and does not provide any current diagnostic value over ferritin
and other available iron studies. This target continues to be
widely studied and may hold promise as an important biomarker
of iron metabolism and a therapeutic target in the future.Conﬂicts of interest
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